{"pmid":32402498,"title":"Non-evidenced based treatment: An unintended cause of morbidity and mortality related to COVID-19.","text":["Non-evidenced based treatment: An unintended cause of morbidity and mortality related to COVID-19.","Am J Emerg Med","Reihani, Hamidreza","Ghassemi, Mateen","Mazer-Amirshahi, Maryann","Aljohani, Bandar","Pourmand, Ali","32402498"],"journal":"Am J Emerg Med","authors":["Reihani, Hamidreza","Ghassemi, Mateen","Mazer-Amirshahi, Maryann","Aljohani, Bandar","Pourmand, Ali"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32402498","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.ajem.2020.05.001","keywords":["covid-19","evidence based medicine","sars-cov-2","therapy","traditional"],"topics":["Treatment"],"weight":1,"_version_":1666714494913478656,"score":9.490897,"similar":[{"pmid":32419721,"pmcid":"PMC7224642","title":"Evidenced-based best practice advice for patients treated with systemic immunosuppressants in relation to COVID-19.","text":["Evidenced-based best practice advice for patients treated with systemic immunosuppressants in relation to COVID-19.","The emergence of the COVID-19 pandemic led to significant uncertainty among physicians and patients about the safety of immunosuppressive medications used for the management of dermatologic conditions. We review available data on commonly used immunosuppressants and their effect on viral infections beyond COVID-19. Notably, the effect of some immunosuppressants on viruses related to SARS-CoV2, including SARS and MERS, has been previously investigated. In the absence of data on the effect of immunosuppressants on COVID-19, these data could be used to make clinical decisions on initiation and continuation of immunosuppressive medications during this pandemic. In summary, we recommend considering the discontinuation of oral JAK inhibitors and prednisone, considering the delay of rituximab infusion, and the careful continuation of cyclosporine, mycophenolate, azathioprine, methotrexate, and biologics in patients currently benefitting from such treatments.","Clin Dermatol","Galimberti, Fabrizio","McBride, Jeffrey","Cronin, Megan","Li, Yumeng","Fox, Joshua","Abrouk, Michael","Herbst, Alexander","Kirsner, Robert S","32419721"],"abstract":["The emergence of the COVID-19 pandemic led to significant uncertainty among physicians and patients about the safety of immunosuppressive medications used for the management of dermatologic conditions. We review available data on commonly used immunosuppressants and their effect on viral infections beyond COVID-19. Notably, the effect of some immunosuppressants on viruses related to SARS-CoV2, including SARS and MERS, has been previously investigated. In the absence of data on the effect of immunosuppressants on COVID-19, these data could be used to make clinical decisions on initiation and continuation of immunosuppressive medications during this pandemic. In summary, we recommend considering the discontinuation of oral JAK inhibitors and prednisone, considering the delay of rituximab infusion, and the careful continuation of cyclosporine, mycophenolate, azathioprine, methotrexate, and biologics in patients currently benefitting from such treatments."],"journal":"Clin Dermatol","authors":["Galimberti, Fabrizio","McBride, Jeffrey","Cronin, Megan","Li, Yumeng","Fox, Joshua","Abrouk, Michael","Herbst, Alexander","Kirsner, Robert S"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32419721","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.clindermatol.2020.05.003","e_drugs":["Cyclosporine","Azathioprine","Prednisone","Rituximab","Mycophenolic Acid","Methotrexate"],"topics":["Treatment"],"weight":1,"_version_":1667159284363821056,"score":59.89413},{"pmid":32425638,"pmcid":"PMC7231497","title":"Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - achieving global consensus and visibility for cellular host-directed therapies.","text":["Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - achieving global consensus and visibility for cellular host-directed therapies.","As of May 11(th) 2020, the coronavirus disease 2019 (COVID-19) pandemic, caused by the novel, the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused 274,361 deaths out of 3,917,366 (7% case fatality rate). As with the two other novel coronavirus zoonotic diseases of humans, SARS and MERS, no specific treatments for reducing mortality or morbidity are yet available. Deaths from COVID-19 will continue to rise globally until effective and appropriate treatments and vaccines are found. With no specific treatments being available for treating COVID-19 patients, the global medical, scientific, pharma and funding communities have rapidly initiated over 500 COVID-19 clinical on a range of antiviral drug regimens, biologics, repurposed drugs in various combinations. We focus this editorial specifically on the background to, and the rationale for, the use and evaluation of mesenchymal stromal (Stem) cells (MSCs) in treatment trials of patients with severe COVID-19 disease. This is an area which has been eclipsed by the current emphasis the huge number of trials evaluating new anti-viral drugs, repurposed drugs and combinations thereof. MSCs should also be trialed for treatment of severe cases of MERS where mortality rates are upto 34% and MERS-CoV remains a WHO priority Blueprint pathogen. It's about time funding agencies now invest more into development MSCs per se and other host-directed therapies in combination with other therapeutic interventions. MSC therapy could turn out to be an important contribution to bringing an end to the high COVID-19 and MERS death rates.","Int J Infect Dis","Zumla, Alimuddin","Wang, Fu-Sheng","Ippolito, Giuseppe","Petrosillo, Nicola","Agrati, Chiara","Azhar, Esam I","El-Kafrawy, Sherif A","Osman, Mohamed","Zitvogel, Laurence","Locatelli, Franco","Gorman, Ellen","O'Kane, Cecilia","Mcauley, Danny","Maeurer, Markus","32425638"],"abstract":["As of May 11(th) 2020, the coronavirus disease 2019 (COVID-19) pandemic, caused by the novel, the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused 274,361 deaths out of 3,917,366 (7% case fatality rate). As with the two other novel coronavirus zoonotic diseases of humans, SARS and MERS, no specific treatments for reducing mortality or morbidity are yet available. Deaths from COVID-19 will continue to rise globally until effective and appropriate treatments and vaccines are found. With no specific treatments being available for treating COVID-19 patients, the global medical, scientific, pharma and funding communities have rapidly initiated over 500 COVID-19 clinical on a range of antiviral drug regimens, biologics, repurposed drugs in various combinations. We focus this editorial specifically on the background to, and the rationale for, the use and evaluation of mesenchymal stromal (Stem) cells (MSCs) in treatment trials of patients with severe COVID-19 disease. This is an area which has been eclipsed by the current emphasis the huge number of trials evaluating new anti-viral drugs, repurposed drugs and combinations thereof. MSCs should also be trialed for treatment of severe cases of MERS where mortality rates are upto 34% and MERS-CoV remains a WHO priority Blueprint pathogen. It's about time funding agencies now invest more into development MSCs per se and other host-directed therapies in combination with other therapeutic interventions. MSC therapy could turn out to be an important contribution to bringing an end to the high COVID-19 and MERS death rates."],"journal":"Int J Infect Dis","authors":["Zumla, Alimuddin","Wang, Fu-Sheng","Ippolito, Giuseppe","Petrosillo, Nicola","Agrati, Chiara","Azhar, Esam I","El-Kafrawy, Sherif A","Osman, Mohamed","Zitvogel, Laurence","Locatelli, Franco","Gorman, Ellen","O'Kane, Cecilia","Mcauley, Danny","Maeurer, Markus"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425638","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.ijid.2020.05.040","keywords":["covid-19 disease","mesenchymal","stromal (stem) cells","therapy","deaths","treatment"],"topics":["Treatment"],"weight":1,"_version_":1667252837762990083,"score":57.789997},{"pmid":32331761,"pmcid":"PMC7151315","title":"Guidance in an uncertain world.","text":["Guidance in an uncertain world.","Br J Anaesth","Moppett, Iain K","Gardiner, Dale","Harvey, Daniel J R","32331761"],"journal":"Br J Anaesth","authors":["Moppett, Iain K","Gardiner, Dale","Harvey, Daniel J R"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32331761","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.bja.2020.04.003","keywords":["covid-19","clinical guidelines","coronavirus","evidence based medicine","guidelines","safety"],"topics":["Prevention"],"weight":1,"_version_":1666138494054957056,"score":54.65207},{"pmid":32360585,"pmcid":"PMC7192075","title":"Current targeted therapeutics against COVID-19: based on first-line experience in china.","text":["Current targeted therapeutics against COVID-19: based on first-line experience in china.","SARS-CoV-2 is a novel strain, causing a global pandemic since the end of 2019. The majority of patients showed nonspecific symptoms such as fever, dry cough, and fatigue. Most patients have a good prognosis while some with severe conditions could rapidly progress to acute respiratory distress syndrome, septic shock, metabolic acidosis, coagulation dysfunction, and even die. The exacerbation of the patient's condition may be due to a cytokine storm in the body. Effective targeted therapies including antiviral and immunization are urgently needed. Although many clinical trials are already underway and the majority of patients have received antiviral therapy based on medication experience with severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), and preliminary results from some clinical trials, there are no antiviral drugs proven to be effective currently. We summarize the current therapeutic medicines used in the clinic, hope to be able to provide some implications for clinical medication.","Pharmacol Res","Zhang, Yue","Xu, Qianhao","Sun, Zhuoyan","Zhou, Lei","32360585"],"abstract":["SARS-CoV-2 is a novel strain, causing a global pandemic since the end of 2019. The majority of patients showed nonspecific symptoms such as fever, dry cough, and fatigue. Most patients have a good prognosis while some with severe conditions could rapidly progress to acute respiratory distress syndrome, septic shock, metabolic acidosis, coagulation dysfunction, and even die. The exacerbation of the patient's condition may be due to a cytokine storm in the body. Effective targeted therapies including antiviral and immunization are urgently needed. Although many clinical trials are already underway and the majority of patients have received antiviral therapy based on medication experience with severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), and preliminary results from some clinical trials, there are no antiviral drugs proven to be effective currently. We summarize the current therapeutic medicines used in the clinic, hope to be able to provide some implications for clinical medication."],"journal":"Pharmacol Res","authors":["Zhang, Yue","Xu, Qianhao","Sun, Zhuoyan","Zhou, Lei"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32360585","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.phrs.2020.104854","keywords":["covid-19","antiviral","immunization","therapy"],"locations":["china"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1666138495899402240,"score":47.46395},{"pmid":32317431,"title":"Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future.","text":["Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future.","A severe form of respiratory disease - COVID-19, caused by SARS-CoV-2 infection, has evolved into a pandemic resulting in significant morbidity and mortality. The unabated spread of the disease is due to lack of vaccine and effective therapeutic agents against this novel virus. Hence, the situation demands an immediate need to explore all the plausible therapeutic and prophylactic strategies that can be made available to stem the spread of the disease. Towards this effort, the current review outlines the key aspects of the pathobiology associated with the morbidity and mortality in COVID-19 patients, which includes a viral response phase and an exaggerated host response phase. The review also summarizes therapeutic agents that are currently being explored along with those with potential for consideration. The broad groups of therapeutic agents discussed include those that: (i) block viral entry to host cells, (ii) block viral replication and survival in host cells, and (iii) dampen exaggerated host immune response. The various kinds of pharmaceutical prophylactic options that may be followed to prevent COVID-19 have also been discussed.","Indian J Ophthalmol","Shetty, Rohit","Ghosh, Arkasubhra","Honavar, Santosh G","Khamar, Pooja","Sethu, Swaminathan","32317431"],"abstract":["A severe form of respiratory disease - COVID-19, caused by SARS-CoV-2 infection, has evolved into a pandemic resulting in significant morbidity and mortality. The unabated spread of the disease is due to lack of vaccine and effective therapeutic agents against this novel virus. Hence, the situation demands an immediate need to explore all the plausible therapeutic and prophylactic strategies that can be made available to stem the spread of the disease. Towards this effort, the current review outlines the key aspects of the pathobiology associated with the morbidity and mortality in COVID-19 patients, which includes a viral response phase and an exaggerated host response phase. The review also summarizes therapeutic agents that are currently being explored along with those with potential for consideration. The broad groups of therapeutic agents discussed include those that: (i) block viral entry to host cells, (ii) block viral replication and survival in host cells, and (iii) dampen exaggerated host immune response. The various kinds of pharmaceutical prophylactic options that may be followed to prevent COVID-19 have also been discussed."],"journal":"Indian J Ophthalmol","authors":["Shetty, Rohit","Ghosh, Arkasubhra","Honavar, Santosh G","Khamar, Pooja","Sethu, Swaminathan"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32317431","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.4103/ijo.IJO_639_20","keywords":["covid-19","sars-cov-2","prophylaxis","therapy"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138493673275392,"score":41.70985}]}